ZRANB2 and SYF2-mediated splicing programs converging on ECT2 are involved in breast cancer cell resistance to doxorubicin
Open Access
- 16 January 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 48 (5), 2676-2693
- https://doi.org/10.1093/nar/gkz1213
Abstract
Besides analyses of specific alternative splicing (AS) variants, little is known about AS regulatory pathways and programs involved in anticancer drug resistance. Doxorubicin is widely used in breast cancer chemotherapy. Here, we identified 1723 AS events and 41 splicing factors regulated in a breast cancer cell model of acquired resistance to doxorubicin. An RNAi screen on splicing factors identified the little studied ZRANB2 and SYF2, whose depletion partially reversed doxorubicin resistance. By RNAi and RNA-seq in resistant cells, we found that the AS programs controlled by ZRANB2 and SYF2 were enriched in resistance-associated AS events, and converged on the ECT2 splice variant including exon 5 (ECT2-Ex5+). Both ZRANB2 and SYF2 were found associated with ECT2 pre-messenger RNA, and ECT2-Ex5+ isoform depletion reduced doxorubicin resistance. Following doxorubicin treatment, resistant cells accumulated in S phase, which partially depended on ZRANB2, SYF2 and the ECT2-Ex5+ isoform. Finally, doxorubicin combination with an oligonucleotide inhibiting ECT2-Ex5 inclusion reduced doxorubicin-resistant tumor growth in mouse xenografts, and high ECT2-Ex5 inclusion levels were associated with bad prognosis in breast cancer treated with chemotherapy. Altogether, our data identify AS programs controlled by ZRANB2 and SYF2 and converging on ECT2, that participate to breast cancer cell resistance to doxorubicin.Funding Information
- Fondation pour la Recherche Médicale (DBI20141231314)
- Institut National Du Cancer (2015-141)
- Ligue Nationale Contre le Cancer
- Ministère de l’Enseignement Supérieur et de la Recherche Scientifique
- MRC (MR/N012097/1)
- CRUK (C37/A12011)
- Institut Curie (ANR-10-EQPX-03, ANR-10-INBS-09-08)
- Cancéropôle Ile-de-France
- SiRIC-Curie program (INCa-DGOS-4654)
This publication has 56 references indexed in Scilit:
- ZRANB2 localizes to supraspliceosomes and influences the alternative splicing of multiple genes in the transcriptomeMolecular Biology Reports, 2013
- Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression?Cellular and Molecular Life Sciences, 2012
- Disruption of Murine mp29/Syf2/Ntc31 Gene Results in Embryonic Lethality with Aberrant Checkpoint ResponsePLOS ONE, 2012
- The Nuclear Guanine Nucleotide Exchange Factors Ect2 and Net1 Regulate RhoB-Mediated Cell Death after DNA DamagePLOS ONE, 2011
- Prolonged Drug Selection of Breast Cancer Cells and Enrichment of Cancer Stem Cell CharacteristicsJNCI Journal of the National Cancer Institute, 2010
- Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhingedGenes & Development, 2010
- Cdc5L interacts with ATR and is required for the S‐phase cell‐cycle checkpointEMBO Reports, 2009
- Twist1-Mediated Adriamycin-Induced Epithelial-Mesenchymal Transition Relates to Multidrug Resistance and Invasive Potential in Breast Cancer CellsClinical Cancer Research, 2009
- The zinc fingers of the SR-like protein ZRANB2 are single-stranded RNA-binding domains that recognize 5′ splice site-like sequencesProceedings of the National Academy of Sciences of the United States of America, 2009
- Silencing of p29 Affects DNA Damage Responses with UV IrradiationCancer Research, 2006